

The Millennium's 28-Biomarker Panel Handbook

Mark L. Gordon, MD

The Millennium Office Assistant

An Expert-AI System for integrative hormonal analyses

The Millennium's 28-Point Biomarker Panel Handbook

Mark L. Gordon, MD (2025) https://MillenniumAPP.ai

Forward

In 2015, with the publication of *TBI: A Clinical Approach to Diagnosis and Treatment*, the 28-point biomarker panel was formally introduced to the medical community as a new paradigm in evaluating neuroendocrine and neuroinflammatory dysfunction. Chapter 6 of that book devoted 41 pages to explaining the philosophy, application, and interpretation of the panel—providing clinicians with a comprehensive framework for understanding the underlying biochemical disruptions associated with traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and systemic endocrine disorders.

Despite the depth and breadth of content presented, it soon became evident that the complexity of the biomarker panel—particularly the interrelationships between individual markers—led to a form of cognitive overload for many practitioners. The volume of data, while robust, required a level of integration and interpretation that exceeded the capabilities of traditional clinical analysis. This challenge inspired the conceptualization of a next-generation solution: a machine-learning-based application capable of analyzing each biomarker within a multi-dimensional matrix, accounting for hormonal cascades, conversion dynamics, inflammatory feedback, and disease-specific patterns.

The result of this vision is the **Millennium Office Laboratory Assistant (MOA)**—an expert AI-driven platform designed to evaluate the 28-point panel in real time. MOA identifies not only absolute deficiencies and insufficiencies but also nuanced, pattern-based anomalies often seen in complex conditions such as subclinical hypothyroidism, occult inflammatory states, and early-stage pituitary microadenomas. From this analysis, the system generates a predictive and personalized treatment protocol tailored to the unique biochemical fingerprint of each patient.

After nine years of iterative development and refinement, the MOA—powered by the analysis of over 3,000 patient cases—was launched in Beta in September 2022. This achievement would not have been possible without the invaluable contributions of my partner in innovation, Mr. Samuel Nee, whose dedication and technical expertise helped bring the concept to reality. In parallel, I pursued formal academic training in artificial intelligence, earning a certificate in *AI in Healthcare* from the MIT Sloan School of Management in March 2022. According to MIT, the MOA development process fully aligns with the rigorous standards required for clinically viable analytical software.

Science, however, is not static. As our collective understanding of the neuroendocrine and endocrine systems continues to evolve, so too does the MOA. Regular updates ensure that the software remains on the cutting edge of biomedical insight, incorporating the latest peer-reviewed research and clinical findings.

This handbook represents the next step in that journey—providing clinicians, researchers, and healthcare professionals with a distilled, accessible reference to understand the power and utility of the Millennium 28-Point Biomarker Panel. It is my hope that this work will deepen your appreciation for the intricate balance of the human biochemical network and offer practical tools to restore that balance in those we serve.

Mark L. Gordon, MD

Introduction

In traditional post-graduate medical education, clinical laboratory results have often been interpreted as isolated, discrete data points—akin to line items in an accounting ledger. Conventional analysis typically emphasized single-axis reviews, such as renal, hepatic, or thyroid panels, with minimal attention given to the crosstalk between systems. As a result, many deeper biochemical and neuroendocrine relationships have historically been overlooked or misunderstood.

The Millennium Office Laboratory Assistant fundamentally transforms this linear approach by introducing an advanced, integrative model that cross-analyzes all 28 parameters within the Millennium Biomarker Panel. By evaluating inter-parameter dynamics, the MOA uncovers subtle biochemical disruptions, patterns, and correlations that provide a richer, systems-level understanding of patient physiology.

This multidimensional approach has significantly enhanced our diagnostic precision. For instance, the MOA has consistently identified a reproducible pattern of elevated DHEA and DHEA-S in conjunction with low free testosterone in individuals with underlying Mercury (Hg) and/or Lead (Pb) toxicity. Such insights prompt environmental toxicity assessments that might otherwise be delayed or missed.

In another clinical correlation, the MOA flagged the frequent pairing of low serum Vitamin D and elevated reverse T3 (rT3), which has served as a biochemical signature in early or subclinical Hashimoto's Thyroiditis. This flagged combination triggers the recommendation to evaluate thyroid peroxidase (TPO) antibodies, confirming the autoimmune nature of the disorder in many cases.

As time permits, I will continue to share reviews and interpretations of each biomarker included in the MOA analysis. Understanding these intricate biochemical and hormonal interdependencies will not only enhance your clinical acumen but also allow you to educate your patients with greater clarity and confidence—ultimately leading to more targeted and effective treatment protocols.

The Millennium Office Assistant

An Expert-AI System for integrative hormonal analyses

Contents

The 28-Point Biomarker Panel

Growth Hormone (GH):

Growth Hormone (GH), or somatotropin, is a peptide hormone secreted by the anterior pituitary in response to hypothalamic growth hormone-releasing hormone (GHRH) and inhibited by somatostatin. While GH is classically associated with childhood growth, it remains vital throughout adulthood for tissue repair, immune modulation, fat metabolism, cognitive function, cardiovascular health, and cellular regeneration.

GH is secreted in pulsatile bursts, with peak levels occurring during deep (slow wave) sleep. This pulsatility makes isolated GH measurements unreliable as a diagnostic tool. Instead, IGF-1 (Insulin-like Growth Factor 1), a stable surrogate produced in the liver in response to GH, is often used to infer GH status and is included in the Millennium 28-Point Biomarker Panel. However, GH itself is still measured and evaluated in the broader context of pituitary reserve, especially in individuals with suspected hypopituitarism, TBI, or chronic neuroendocrine disruption.

GH deficiency in adults is frequently underdiagnosed but can have widespread consequences. Clinical symptoms include fatigue, abdominal weight gain, reduced muscle mass, decreased exercise capacity, poor recovery from injury, low bone mineral density, insulin resistance, and cognitive decline. These symptoms overlap significantly with those seen in individuals with traumatic brain injury (TBI), PTSD, or chronic inflammation, all of which are prevalent in the patient populations monitored by the Millennium model.

In the neuroendocrine context, GH plays an integral role in neuroplasticity, neuroprotection, and mitochondrial support. It influences memory consolidation, promotes hippocampal neurogenesis, and improves cerebral glucose utilization. GH also indirectly supports the adrenal, thyroid, and gonadal axes by preserving lean body mass and promoting systemic metabolic stability.

The Millennium Office Laboratory Assistant (MOA) evaluates GH levels alongside IGF-1, cortisol, DHEA, testosterone, and thyroid hormones to assess both anabolic status and the integrity of hypothalamic-pituitary signaling. A low GH value, particularly when combined with low IGF-1, is a strong indicator of functional somatotropic deficiency, often found in patients with post-concussive syndromes, chronic fatigue, fibromyalgia, or metabolic decline following endocrine disruption.

In summary, Growth Hormone is a master regulator of repair, regeneration, and metabolic vitality. Its integration within the Millennium 28-Point Panel provides a window into the body's capacity to recover from trauma, inflammation, and stress, and its restoration can dramatically improve patient outcomes when properly identified and supported.

1. Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Vance, M. L., et al. (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96, 1587–1609.
2. Ghigo, E., Arvat, E., Gianotti, L., Camanni, F., & Martini, L. (1997). Growth hormone secretion in adult life. Acta Paediatrica Supplement, 432, 82–92.
3. Pinto, G., Garrel, G., & Bouillanne, O. (2005). Adult-onset growth hormone deficiency and cognitive decline. Hormone Research, 63(Suppl. 1), 24–28.
4. Takahashi, T., Kawamata, T., Mukai, C., & Ishizuka, Y. (2011). Neurological actions of growth hormone and IGF-I on the brain. Frontiers in Neuroendocrinology, 32, 21–40.
5. Johannsson, G., Bengtsson, B. Å., Monson, J. P., & Bosaeus, I. (1997). Growth hormone replacement in adults: effects on physical performance and body composition. Journal of Clinical Endocrinology & Metabolism, 82, 727–734.
6. van Bunderen, C. C., Deijen, J. B., Drent, M., & van der Veen, E. A. (2018). Effects of low-normal and high-normal IGF-1 levels on memory and well-being during GH replacement therapy: a randomized trial in adults with GH deficiency. Health and Quality of Life Outcomes, 16, 135.

7. Arwert, L. I., Van De Pol, A. J., Banahene, J., Hoekstra, T., & Spauwen, P. H. (2004). Effects of GH on bone and muscle in adults: a meta-analysis. Journal of Clinical Endocrinology & Metabolism, 89, 48–55.
8. Johnston, J. E., Sonntag, W. E., & Freeman, W. M. (2013). Role of growth hormone in hippocampal plasticity and memory. Journal of Endocrinology, 217, R1–R14.
9. Schneider, C. R., Beumer, D., Strasburger, C. J., & Dreyer, W. J. (2020). Cardio-metabolic changes associated with adult-onset growth hormone deficiency. Endocrine Reviews, 41, 33–58.
10. Clemmons, D. R. (2004). Modifying IGF-1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature Reviews Drug Discovery, 3, 979–990.

Insulin-like Growth Factor 1 (IGF-1)

IGF-1 is a peptide hormone primarily produced in the liver in response to stimulation by Growth Hormone (GH) and serves as the main mediator of GH's systemic anabolic effects. Unlike GH, which is secreted in pulsatile bursts and varies throughout the day, IGF-1 has a longer serum half-life, making it a more stable and reliable marker of GH axis function. Within the Millennium 28-Point Biomarker Panel, IGF-1 is utilized as a central indicator of cellular regeneration, metabolic resilience, and neuroendocrine repair capacity.

IGF-1 plays a vital role in protein synthesis, muscle maintenance, glucose regulation, neurogenesis, immune function, and mitochondrial biogenesis. It also supports the actions of testosterone, thyroid hormone, and DHEA, making it a hub of anabolic signaling across multiple endocrine axes.

Low IGF-1 levels in adults are associated with a spectrum of symptoms and conditions including fatigue, impaired healing, increased body fat, sarcopenia, bone density loss, insulin resistance, poor recovery from illness, and cognitive decline. These manifestations are especially pronounced in individuals with traumatic brain injury (TBI), post-concussive syndrome, PTSD, chronic inflammation, or HPA-axis dysregulation—all populations commonly evaluated with the Millennium protocol.

IGF-1 has profound effects on the central nervous system, crossing the blood-brain barrier and binding to receptors in regions like the hippocampus and prefrontal cortex, where it enhances BDNF (brain-derived neurotrophic factor) expression, supports synaptic plasticity, and facilitates neuroregeneration. A deficiency in IGF-1 can result in impaired memory, mood instability, and reduced stress adaptability.

Importantly, IGF-1 is nutritionally and hormonally sensitive. Suboptimal protein intake, caloric restriction, low insulin, hypothyroidism, and chronic inflammation can all suppress hepatic IGF-1 production—even in the presence of normal GH secretion. Therefore, interpretation of IGF-1 must be contextualized within the broader functional endocrinology matrix, including GH, cortisol, thyroid function, insulin, DHEA, and testosterone.

In the Millennium Office Laboratory Assistant (MOA) framework, a low IGF-1 level—especially when paired with low GH, testosterone, or T3—is a red flag for impaired repair signaling. It may signal pituitary dysfunction or a systemic block in regenerative capacity, prompting deeper investigation into sleep quality, micronutrient status (e.g., zinc, selenium, magnesium), mitochondrial function, and inflammation.

In summary, IGF-1 serves as a biological barometer of growth, repair, and vitality. Its interpretation within the Millennium system allows for early detection of regenerative deficits and guides interventions that can restore performance, cognition, and quality of life—especially in those recovering from trauma, illness, or chronic stress.

1. Aberg, N. D., Brywe, K. G., & Isgaard, J. (2006). Improved recovery after experimental traumatic brain injury in mice deficient in insulin-like growth factor-binding protein 1 (IGFBP-1). European Journal of Neuroscience, 23(1), 104–110.

2. Trejo, J. L., Carro, E., & Torres-Alemán, I. (2001). Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. The Journal of Neuroscience, 21(5), 1628–1634.
3. DeBoer, M. D., & Lima, G. A. B. (2019). Insulin-like growth factor-1: A modifiable contributor to cognitive decline and dementia. Frontiers in Aging Neuroscience, 11, 232.
4. Sonntag, W. E., Lynch, C. D., Cooney, P. T., & Hutchins, P. M. (1997). Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor I. Endocrinology, 138(8), 3515–3520.
5. Bondanelli, M., Ambrosio, M. R., Zatelli, M. C., De Lellis, L., & degli Uberti, E. C. (2005). Hypopituitarism after traumatic brain injury. European Journal of Endocrinology, 152(5), 679–691.
6. Dyer, A. H., Vahdatpour, C., Sanfeliu, A., & Tropea, D. (2016). The role of insulin-like growth factor 1 (IGF-1) in brain development, maturation and neuroplasticity. Neuroscience, 325, 89–99.
7. Carro, E., Nuñez, A., Busiguina, S., & Torres-Alemán, I. (2000). Circulating insulin-like growth factor I mediates effects of exercise on the brain. The Journal of Neuroscience, 20(8), 2926–2933.
8. Heemskerk, V. H., Daemen, M. A., & Buurman, W. A. (1999). Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine & Growth Factor Reviews, 10(1), 5–14.
9. Svensson, J., Bengtsson, B. A., & Johannsson, G. (2003). Insulin-like growth factor-1 and cognition in adults: Growth hormone replacement therapy and cognitive function. Growth Hormone & IGF Research, 13(4), 262–270.
10. O'Connor, J. C., Johnson, D. R., Freund, G. G., Hansen, M. K., & Kelley, K. W. (2003). Growth hormone and IGF-1 modulate cytokine expression and activation of the JAK-STAT signaling pathway in the immune system. Brain, Behavior, and Immunity, 17(3), 226–239.

Insulin-Like Growth Factor-Binding Protein-3 (IGF-BP3):

In the liver, insulin-like growth factor-binding proteins (IGFBPs) are synthesized by both hepatocytes and nonparenchymal cells, including Kupffer cells and hepatic stellate cells, under the influence of growth hormone (GH). There are seven known IGFBPs (BP-1 through BP-7), each with distinct physiological roles. Notably, IGFBP-3 has been identified for its anti-cancer properties, while IGFBP-1 exhibits cardioprotective effects. Despite their clinical relevance, no current laboratory offers comprehensive testing for the full IGFBP profile.

IGFBP-3 is the predominant binding protein for Insulin-like Growth Factor 1 (IGF-1) in circulation, responsible for stabilizing, transporting, and regulating over 80% of IGF-1 in an inactive reservoir-bound state. This binding prolongs IGF-1's half-life from mere minutes to several hours and modulates its access to IGF-1 receptors, thereby controlling its biological activity. IGFBP-3 synthesis occurs primarily in the liver and is regulated by GH but is also influenced by thyroid hormones, cortisol, sex steroids, inflammatory cytokines, and nutritional status. This makes IGFBP-3 an important contextual marker for evaluating the integrity of the GH-IGF axis and the body's potential for endocrine and neuroregenerative recovery.

Within the Millennium 28-Point Biomarker Panel, IGFBP-3 enhances the interpretive value of IGF-1 by helping to distinguish between production deficits and binding abnormalities. For instance, a normal IGF-1 level accompanied by low IGFBP-3 may indicate insufficient GH stimulation or hepatic dysfunction. In contrast, elevated IGFBP-3 with low IGF-1 may suggest abnormal binding protein overexpression, leading to reduced IGF-1 availability at the receptor level. When both IGF-1 and IGFBP-3 are low, the pattern often points to GH deficiency, pituitary impairment, or systemic inflammation disrupting anabolic signaling.

Beyond its role as a transport protein, IGFBP-3 exerts several IGF-independent actions. It has demonstrated pro-apoptotic and anti-proliferative effects, particularly within the context of cancer biology. Additionally, it modulates cell adhesion, extracellular matrix remodeling, and plays a role in regulating insulin sensitivity, immune function, and neuroinflammation. In the context of neurological and trauma recovery, the balance between IGF-1 and IGFBP-3 becomes especially critical. Excessive IGFBP-3 can sequester IGF-1, limiting its beneficial actions in the hippocampus, cerebral cortex, and spinal cord, which may impair tissue repair and